There are many ways to make money on Wall Street, but some methods are a lot more reliable than others. Whether you're ...

Kathy Davis of Canonsburg underwent heart surgery, but complications left her with right heart failure, a condition where the ...

Expected out-of-pocket costs for commonly prescribed brand name medications have grown substantially for Medicare Part D ...

Medicare changes will cut $1 billion from 2025 revenue, with Pfizer now responsible for 20% of catastrophic drug costs. Read ...

PFE offers a 6.73% dividend yield and growth potential, driven by strategic acquisitions, R&D, and discounted valuations.

Expected out of-pocket costs for commonly prescribed brand name medications have grown substantially for Medicare Part D ...

The OCEANIC-AF trial has raised concerns about factor XI inhibitors. Should physicians still bet on this class of ...

In the Q4 earnings call, the company stated that it has focused its R&D portfolio on four key therapeutic areas: oncology, ...

Pfizer (NYSE: PFE) has been around for 175 years, but the company's revenue soared to its highest ever only in more recent ...

With the robust demand for personalized medicines and the growing adoption of digital technology, the precision medicine ...

In the fourth quarter of 2024, BB Biotech shares posted a total return of -2.7% in CHF and -3.5% in EUR. NAV performance improved, rising by 2.7% in CHF and 2.8% in EUR, though it declined by 4.3% in ...